Leukocyte CH25H is a potential diagnostic and prognostic marker for lung adenocarcinoma

doi:10.21203/rs.3.rs-1948302/v1

Download PDF

Article

Leukocyte CH25H is a potential diagnostic and prognostic marker for lung adenocarcinoma

https://doi.org/10.21203/rs.3.rs-1948302/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Objectives

Metastasis, a major challenge during the treatment of lung cancer, causes deterioration in patient health outcomes. Thus, to address this problem, this study aimed to explore the role and contribution of Cholesterol 25-Hydroxylase (CH25H) as a potential diagnostic and prognostic marker in lung cancer.

Materials/methods

Online public databases were used to analyze the differential expression, prognostic value, gene-pathway enrichment, and immune infiltration of CH25H in lung cancer patients. The Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) was used to analyze and detect the CH25H expression levels in leukocytes from lung cancer patients.

Results

The expression level of CH25H was significantly reduced in lung adenocarcinoma (LUAD), which is associated with a higher disease stage, but not in lung squamous cell carcinoma (LUSC). Kaplan–Meier survival analysis indicated that LUAD patients with low CH25H expression had a worse prognosis. Mechanistically, our results showed that in LUAD, CH25H may be a regulatory factor affecting the immune cell infiltration level, and the resultant tumor development. Experimental data showed that low expression of CH25H in leukocytes was significantly associated with LUAD metastasis (P < 0.01).

Conclusion

Our study suggests that CH25H may function as a prognostic and risk stratification biomarker for LUAD.

LUAD

LUSC

CH25H

immune infiltration

mRNA expression

Lung cancer (LC) is the most common malignancy, causing more than 21% of the cancer-related deaths in China ⁽¹⁾. The high recurrence and metastasis rates of LC have worsened the prognosis in patients ⁽²⁾. Therefore, the discrimination and intervention of treatment techniques in patients with a high risk of metastasis could greatly contribute to the improvements in clinical efficacy and ultimate survival.

Novel approaches, such as liquid biopsy, employing the detection of tumor-derived circulating cell-free DNA/RNA, are powerful clinical strategies in the supervision of cancer progression because of their high sensitivity or specificity ^(3-5). However, owing to technical difficulties and costs, these detection approaches are difficult to implement. Therefore, there is a need to develop cheaper and simpler methods and techniques that employ the detection of new biomarkers for predicting LC prognosis. Many small molecules, such as LKB1, RASSF1A, and HOXB13, have been reported to be associated with LC recurrence and metastasis^(6-8). Notably, a recent study showed that low mRNA expression of CH25H in leukocytes of melanoma patients is associated with a poor prognosis ⁽⁹⁾. The proportion of patients with melanoma having high CH25H expression was 54.9% in the non-metastatic group. This was significantly higher than that in the metastatic group (14.8 %). In addition, researchers found that overall survival was significantly higher in patients with high CH25H expression than in those with low CH25H expression, suggesting that CH25H expression may act as an independent prognostic factor for predicting distant metastasis of breast cancer ⁽¹⁰⁾.

However, the expression, prognostic value, and mechanism of CH25H in lung cancer have not been reported. This study explored the relationship between CH25H expression and lung tumor metastasis and its potential mechanism by multidimensional bioinformatics analysis and preliminary confirmation by leukocyte experiments.

CH25H expression analyses by public database

GEPIA (http://gepia.cancer-pku.cn/), a newly developed interactive web server was used to analyze the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) projects⁽¹¹⁾. This study performed a comparative analysis of the differential expression of CH25H in tumor and normal tissues. The Student’s t-test was used to generate p-values for expression.

UALCAN (http://ualcan.path.uab.edu/) is a comprehensive, user-friendly, and interactive web resource that provides easy access to publicly available cancer omics datasets such as TCGA, MET500, and Clinical Proteomic Tumor Analysis Consortium (CPTAC)⁽¹²⁾. The expression data for CH25H based on different clinical baselines were obtained from the “Expression” submodule of the “TCGA Gene analysis” module. The Student’s t-test was used to generate a p-value, and statistical significance was set at p < 0.05.

TIMER (https://cistrome.shinyapps.io/timer/) is a comprehensive resource for the systematic analysis of the abundance of six immune infiltrates (B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells) across diverse cancer types⁽¹³⁾. In this study, “Diff Exp” module was used to study the differential expression of CH25H between tumor and adjacent normal tissues across all TCGA tumors. Distribution of gene expression levels are displayed using box plots, with the Wilcoxon test evaluating the statistical significance of differential expression.

CH25H prognostic value analyses

Overall survival (OS) data of CH25H in LC were analyzed using TIMER. The high- and low-expression groups were cut off by the median expression of CH25H. The Kaplan-Meier (K-M) graph was exported with axis units of months, and the log-rank p-value, hazard ratio (HR), and 95% confidence interval curve are shown in each graph.

Gene-pathway enrichment analysis of CH25H

In this study, the analytical module LinkFinder of LinkedOmics ⁽¹⁴⁾ (http://www.linkedomics.org/) provided co-expression gene sets of CH25H in patients with LC. Metascape ⁽¹⁵⁾ (https://metascape.org/) was used to generate gene ontology (GO) enrichment and pathway networks of CH25H.

Immune infiltration analysis

Sangerbox Tools (http://www.sangerbox.com/tool) are a free online platform for comprehensive data analysis. We used Sangerbox Tools to estimate the correlation between CH25H expression and immune infiltration level in LC patients according to previous literature ⁽¹⁶⁾ and combined it with data from TCGA for prognosis and immunotherapy analysis.

Ethics approval and consent to participate

This study was conducted according to the principles of the World Medical Association Declaration of Helsinki and approved by the ethics committee of the second Hospital of Jiaxing (IRB approval No. jyey2017023). All participants provided written informed consent for this study. Other datasets were retrieved from the published literature, so it was confirmed that all written informed consent was obtained.

Patient selection and evaluation

The patients included in this study had primary LC treated at the Second Hospital of Jiaxing (Zhejiang, China) from June 2019 to August 2020. The cancer was diagnosed by clinical and X-ray findings and confirmed via histology of tumor biopsies. The inclusion criteria included previously employed surgery and/or standardized treatment and histological confirmation of non-small cell lung cancer (NSCLC). The exclusion criteria included multiple organ dysfunction or a history of organ transplantation, small cell lung cancer (SCLC), unwillingness to participate in the study, and cessation of therapy. Data regarding the clinical characteristics were carefully collected.

Determination of CH25H mRNA expression

The blood specimens (10 mL) from all the enrolled patients were collected and centrifuged at 2500 rpm for 10 min within 2 h of their collection to separate the leukocytes. Total RNA extraction from leukocytes was performed using an RNA Plus Kit (Yunying, Jiaxing, China). Reverse transcription was performed using the HiScript® III 1st Strand cDNA Synthesis Kit (Vazyme, Nanjing, China), and qRT-PCR analysis was performed using the Alldetect™ kit (Yunying, Jiaxing, China) on an ABI 7500 system (ThermoFisher, MA, USA). The TaqMan assay was used for qRT-PCR amplification detection. Ribosomal protein LO (RPLO) was used as the reference gene, and primers and probes (Table S1) were designed using Primer Premier 5.0 (Premier Biosoft, CA, USA), and synthesized by General Biotech (Shanghai, China). Each process was strictly performed according to the manufacturer’s protocol.

Statistical analyses

The differential expression of CH25H across different LC groups was analyzed by the Mann-Whitney U test. Statistical analyses were performed with SPSS v.22.0 (IBM Corp., New York, USA). Statistical graphs were generated by the R package “ggplot2”. A P < 0.05 was considered statistically significant and was used as the inclusion standard in the analysis.

CH25H expression level downregulated in LUAD and correlated with prognosis

We analyzed the differential expression of CH25H in lung tumor tissues and normal tissues using online databases (Fig. 1A and 1B). The CH25H expression levels showed significant differences (p < 0.01) during different disease stages (stage1 - 4) in LUAD (Fig. 1C), but not in LUSC (Fig. 1D). We observed that in LUAD, this negative expression was significantly associated with sex (Fig. S1B), and nodal metastasis status (Fig. S1F). Other factors such as age (Fig. S1A), race (Fig. S1C), smoking habits (Fig. S1D), and histological subtypes (Fig. S1E) showed poor correlation with CH25H expression. However, in patients with LUSC, no outstanding relationship between CH25H expression and these factors was observed (Fig. S2).

The survival difference was evaluated, and results showed that compared with the low expression cohort, patients in the high expression cohort showed a significantly enhanced OS (P < 0.01, N = 478), indicating a better prognosis (Fig. 1E). However, compared with the lower expression cohort, LUSC patients with high CH25H expression showed a reduced trend of survival time in both OS, although the difference was not statistically significant (P > 0.05, N = 481, Fig. 1F).

CH25H associated with immune regulation

Heat maps showed that the top 20 significant genes were positively and negatively related to CH25H in LUAD (Fig. 2A–2B) and LUSC (Fig. 2E-2F), respectively. Notably, 6/20 genes (CD1C, CD74, HLA-DPB1, NLRP3, ADRB2 and AMICA1) were positively related to CH25H in LUAD. They were therefore responsible for the positive regulation of the immune system ^(17-22). Pathway analysis revealed an enriched immune regulation, such as the regulation of leukocyte activation, positive regulation of immune response, and adaptive immune system (Fig. 2C and 2D). However, in LUSC, CH25H showed a weak association with the immune regulation, as analyzed by gene enrichment (Fig. 2E and 2F) and pathway analysis (Fig. 2G and 2H). These results could possibly explain the importance of CH25H as a prognostic biomarker in case of LUAD only. It was therefore hypothesized that CH25H controls the spread and infiltration of tumor cells via immune regulation in LUAD.

Some studies have found that biomarkers such as CLEC3B ⁽²⁶⁾ and YTHDF1/YTHDF2 ⁽²⁷⁾ affect the immune microenvironment, and metastasis and prognosis of lung cancer. Therefore, we studied the correlation between CH25H expression and immune cell infiltration.

CH25H expression level associated with immune infiltration level

We hypothesized that CH25H expression regulates the infiltration levels of immune cells. We also investigated the relationship between CH25H expression and the abundance of immune infiltrates. The results showed that CH25H expression level was less associated with the infiltration of immune cells (for instance, B cells, T cells, and macrophages) in the LUSC subtype. However, the expression of CH25H was significantly positively correlated with immune cell infiltration in LUAD (Fig. 3A). These results confirmed that CH25H expression potentially regulates the immune infiltration in patients with LUAD.

In addition, we observed that CH25H expression was significantly correlated with immune infiltration in LUAD (Fig. 3B -3D), better than in LUSC (Fig. 3E–3G), as evaluated by stromal, immune, and comprehensive ESTIMAT, respectively.

Immune infiltration level associated with prognosis in LUAD

We further investigated the relationship between immune score and OS of LC patients, and the results (Fig. 4A and 4B) were similar to the result of CH25H expressional level and OS (Fig. 1E and 1F). The survival difference results showed that, compared with the low immune score cohort, the high immune score cohort showed a significantly enhanced OS (P < 0.05) in LUAD (Fig. 4A). Similar analyses were performed for LUSC, but the opposite result was obtained (P > 0.05, Fig. 4B).

CH25H level associated with immunotherapy in LUAD

Immunotherapy molecular marker analysis revealed that both, CD274 (P < 0.001) and CTLA4 (P < 0.01) significantly correlated with CH25H expression in LUAD (Fig. 4C and 4D), this was not seen in the case of PDCD1 (Fig. S3 (left)). However, in LUSC, only CD274 was significantly related to CH25H expression (Fig. 4E) but not CTLA4 (Fig. 4F) or PDCD1 (Fig. S3 (right)). The results of this study indicate that CH25H can be a potential biomarker for predicting immunotherapy efficacy.

Leukocytes CH25H expression level related to the lung tumor metastasis

To confirm the role of CH25H in lung cancer, we conducted a preliminary clinical study using leukocyte samples from patients having lung cancer. This study employed 34 patients newly diagnosed with LC between 2019 and 2020. The average age at the time of diagnosis was 64 years and the median age of the cohort was 65 years (range, 38–88 years). Other characteristics of the study participants are listed in Table 1.

Based on the tumor metastasis status, the patients were divided into metastatic and non-metastatic groups. Blood samples were collected to detect CH25H mRNA expression levels in leukocytes. The results showed that, in LUAD patients, CH25H expression was significantly decreased in the metastatic group (P < 0.01, Fig. 5). However, no significant decrease in the CH25H expression was observed in LUSC patients with tumor metastasis (P > 0.05, Fig. 5), indicating that the CH25H expression level is a potential biomarker for LC metastasis prediction, especially in LUAD.

Previous research has shown that low CH25H levels in leukocytes correlate with poor prognosis in melanoma patients⁽⁹⁾. Mechanistically, CH25H catalyzes cholesterol oxidation, wherein cholesterol is metabolized to 25-hydroxycholesterol (25-HC) in vivo, which could resist the normal cell absorption of the TEVs (tumor-derived extracellular vesicles), indicating the important role of CH25H in defense against the production of the tumor pre-metastatic microenvironment. In this study, we found that low CH25H levels were correlated with poor prognosis in patients with LUAD (Fig. 1E).

Genes co-expressed with CH25H were analyzed to understand the underlying mechanism of CH25H in LUAD. We found that some genes that were positively related to CH25H were related to immunity (CD1C, CD74, HLA-DPB1, NLRP3, ADRB2 and AMICA1) (Fig. 2A). According to Di Blasio et al., CD1C (+) dendritic cells (DCs) can elicit immunogenic cell death (ICD) ⁽¹⁷⁾. Overexpression of HLA-DPB2 promotes tumor immune infiltration by regulating HLA-DPB1, which is associated with a high survival rate in breast cancer⁽¹⁸⁾. Lu et al. showed that NLRP3 inflammasome blockade down-regulates the expression of PD-L1 and reduces the immunosuppression of lymphoma ⁽¹⁹⁾. The expression of ADRB2 is positively correlated with the infiltration of immune cells in breast cancer, especially the T cells ⁽²⁰⁾. Activated cGAS-STING signaling in LUAD by AMICA1 induces immune cell infiltration ⁽²¹⁾. High infiltration of CD74+ macrophages in hepatocellular cancer is related to higher infiltration of CD8+ cytotoxic T cells (CTL) ⁽²²⁾. These previous studies suggest that CH25H may also be associated with positive regulation of tumor immunity in LUAD. Further, pathway analysis showed that CH25H may participate in several immune-related processes, including regulation of leukocyte activation, positive regulation, immune response, and adaptive immune system (Fig. 2C and 2D), which confirmed our hypothesis.

In our study, according to the Sangerbox tool, we found that CH25H is positively related to the immune score and the infiltration of several immune cells, including B cells, CD4+ T cells, CD8+ T cells, dendritic cells, macrophages, and neutrophils (Fig. 3A), which is consistent with the role of AMICA1 in LUAD according to a previous study ⁽²¹⁾. This means that CH25H may also affect the level of immune cell infiltration through signaling pathways such as cGAS-STING, however, further research is required. The infiltration level of immune cells is closely related to the effectiveness of immunotherapy and classification basis of “hot” (highly infiltrated) and “cold” (non- infiltrated) tumors ⁽²³⁾. High CH25H expression may cause high infiltration level, i.e. “hot” tumor. Furthermore, they may influence the immunotherapy, manifested by an upregulation of the level of immunotherapy molecular markers (such as CD274 and CTLA4, Fig. 4, left plot) in LUAD. Moreover, CD8+ T cells, one of the most important effector cells, play important roles in clearing intracellular pathogens and tumors ⁽²³⁾. So, mechanistically, these results indicated that CH25H may affect tumor progression via immune regulation in LUAD. This may also explain the reason behind the decreased CH25H expression levels with the progression of LUAD (Fig. 1C).

Moreover, leukocyte CH25H expression analysis revealed that CH25H expression levels were significantly down-regulated in the metastatic cohort. The main product of CH25H catalyzed reaction is 25-HC, which has been reported to suppress the migration and proliferation of gastric cancer cells ^{(24, 25)}, and the opposite effect was observed in LUAD ⁽²⁶⁾. Our results are consistent with the outcomes of these studies; when the donor suffered from LUAD, decreased CH25H expression reduced the 25-HC level, thereby possibly promoting tumor metastasis, as shown in Fig. 5. Our hypothesis may explain this phenomenon. Decreased CH25H expression in LUAD may cause low immune cell infiltration, causing tumor cells to escape immune system and promote tumor metastasis, finally leading to poor prognosis, as shown in Fig. 1E and 4A.

However, this study had some limitations. First, further studies consisting of cell experiments and clinical research are required to validate and explore the potential molecular mechanisms underlying the correlation between CH25H expression and immune response. In addition, this was a single-center study with a small sample size. Therefore, prospective multicenter studies involving a larger cohort should be undertaken to expand our understanding of the ability of leukocyte CH25H expression to distinguish between metastatic and non-metastatic LC patients. Most importantly, tumor tissue experiments are needed to verify the accuracy of leukemia results.

Here, through bioinformatics analysis, we speculate that CH25H expression levels are associated with immune cell infiltration. This was confirmed by the detection of CH25H expression in leukocytes. We identified a potential molecular marker for the prognosis and risk stratification of LUAD.

Clinical practice points

Previous studies have indicated that the expression level of CH25H is an independent prognostic factor for predicting distant metastasis of breast cancer and melanoma, however, its prognostic value in lung cancer remains unclear. Our data showed a decreased CH25H expression in LUAD. Notably, low expression of CH25H in leukocytes is an obvious molecular characteristic of metastatic tumors which results in poor prognosis. In addition, increased CH25H expression improves the overall survival time of patients with LUAD, displaying a potential correlation with immune infiltration. Our findings promote an improved understanding of the mechanisms of CH25H in lung cancer and demonstrate that leukocyte CH25H expression could be used to develop a rapid, inexpensive, and powerful diagnostic strategy for predicting the risk of lung cancer metastasis. This study will also serve as a foundation for future large-cohort studies to verify the significance of CH25H expression.

Author contributions

Jun Zhang: Conceptualization, Validation, Investigation, Project administration, Writing - review & editing. Lidong Xu: Methodology, Formal analysis, Investigation, Project administration. Jun Gao: Conceptualization, Data curation, Supervision. Jieyi Li: Methodology, Formal analysis, Writing - original draft, Writing - review & editing, Visualization. Xiaokai Zhao: Methodology, Formal analysis, Writing - review & editing. Pengmin Yang: Writing - original draft. Yujun Ge: Investigation, Resources. Dawei Guo: Methodology, Validation, Investigation. Zhonghua Liu: Investigation, Resources. Xiyong Wang: Resources, Data curation. Wenchao Gu: Resources, Data curation. Pengli Wang: Resources, Data curation. Xun Hu: Validation, Resources. Ziying Gong: Methodology, Formal analysis, Data curation, Supervision, Funding acquisition. Daoyun Zhang: Conceptualization, Data curation, Supervision, Project administration, Funding acquisition. All authors contributed to manuscript revision, read, and approved the submitted version.

Conflict of Interest

Jieyi Li, Xiaokai Zhao, Pengmin Yang, Daoyun Zhang, and Ziying Gong were employed by the Jiaxing Yunying Medical Inspection Co., Ltd., and the Zhejiang Yunying Medical Technology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work was supported by the Bethune Charitable Foundation, the Jiaxing Science and Technology Research Project [grant numbers 2019AD32200, 2018AD32034]; the Zhejiang Leading Talent Entrepreneurship Project [grant number 2021R02019]; the Jiaxing Leading Talent Entrepreneurship Project; and the Key Technology Innovation Projects of Jiaxing [grant number 2021BZ10004].

Data availability statement

The data that supporting the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Chen W, Zheng R, Baade PD, et al: Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians 66: 115-132, 2016.
Wang X and Adjei AA: Lung cancer and metastasis: new opportunities and challenges. Cancer and Metastasis Reviews 34: 169-171, 2015.
Michael Oellerich M, Ekkehard Schütz M, Julia Beck P and Philip D. Walson M: Circulating Cell-Free DNA—Diagnostic and Prognostic Applications in Personalized Cancer Therapy. Therapeutic Drug Monitoring 41: 115-120, 2019.
Szilágyi M, Pös O, Márton É, et al: Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application. Int J Mol Sci 21: 2020.
Oellerich M, Schütz E, Beck J and Walson PD: Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy. Therapeutic Drug Monitoring 41: 115-120, 2019.
Zhan J, Wang P, Li S, et al: HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients. Theranostics 9: 2084-2099, 2019.
Pankova D, Jiang Y, Chatzifrangkeskou M, et al: RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma. EMBO Journal 38: e100532, 2019.
Ji H, Ramsey MR, Hayes DN, et al: LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810, 2007.
Ortiz A, Gui J, Zahedi F, et al: An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell 35: 33-45 e36, 2019.
Mittempergher L, Saghatchian M, Wolf DM, et al: A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Molecular Oncology 7: 987-999, 2013.
Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Research 45: W98-w102, 2017.
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al: UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (New York, NY) 19: 649-658, 2017.
Li T, Fan J, Wang B, et al: TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer research 77: e108-e110, 2017.
Vasaikar SV, Straub P, Wang J and Zhang B: LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Research 46: D956-d963, 2018.
Zhou Y, Zhou B, Pache L, et al: Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature communications 10: 1523, 2019.
Hu J, Qiu D, Yu A, et al: YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy. Frontiers in oncology 11: 607224, 2021.
Di Blasio S, Wortel IM, van Bladel DA, et al: Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology 5: e1192739, 2016.
Lyu L, Yao J, Wang M, et al: Overexpressed Pseudogene HLA-DPB2 Promotes Tumor Immune Infiltrates by Regulating HLA-DPB1 and Indicates a Better Prognosis in Breast Cancer. Frontiers in oncology 10: 1245, 2020.
Lu F, Zhao Y, Pang Y, et al: NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma. Cancer Letters 497: 178-189, 2021.
Wei X, Chen L, Yang A, Lv Z, Xiong M and Shan C: ADRB2 is a potential protective gene in breast cancer by regulating tumor immune microenvironment. Transl Cancer Res 10: 5280-5294, 2021.
Feng Z, Zhang Y, He M, et al: AMICA1 is a diagnostic and prognostic biomarker and induces immune cells infiltration by activating cGAS-STING signaling in lung adenocarcinoma. Cancer cell international 22: 111, 2022.
Xiao N, Li K, Zhu X, et al: CD74(+) macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma. Cancer Immunol Immunother 71: 57-69, 2022.
Galon J and Bruni D: Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18: 197-218, 2019.
Wang S, Yao Y, Rao C, Zheng G and Chen W: 25-HC decreases the sensitivity of human gastric cancer cells to 5-fluorouracil and promotes cells invasion via the TLR2/NF-κB signaling pathway. International journal of oncology 54: 966-980, 2019.
Guo F, Hong W, Yang M, et al: Upregulation of 24(R/S),25-epoxycholesterol and 27-hydroxycholesterol suppresses the proliferation and migration of gastric cancer cells. Biochemical and Biophysical Research Communications 504: 892-898, 2018.
Chen L, Zhang L, Xian G, Lv Y, Lin Y and Wang Y: 25-Hydroxycholesterol promotes migration and invasion of lung adenocarcinoma cells. Biochemical and Biophysical Research Communications 484: 857-863, 2017.

Table 1. Patient characteristics

Characteristics	Patients
*Total number of patients*	34
*Sex*
Male	23 (67.6%)
Female	11 (32.4%)
*Age at diagnosis (years)*
≤60	9 (26.5%)
>60	25 (73.5%)
*Primary tumor size (cm)*
<2	9 (26.5%)
2-5	21 (61.8%)
>5	4 (11.8%)
*Primary tumor stage*
Ⅰ	4 (11.8%)
Ⅱ	7 (20.6%)
Ⅲ	5 (14.7%)
Ⅳ	18 (52.9%)
*Histology*
Adenocarcinoma	23 (67.6%)
Squamous cell carcinoma	11 (32.4%)
*First-line treatment*
Surgery	11 (32.4%)
Chemotherapy	6 (17.6%)
Surgery + Chemotherapy	17 (50.0%)
*Metastasis*
Metastasis	18 (52.9%)
Non-metastasis	16 (47.1%)

Competing interest reported. Jieyi Li, Xiaokai Zhao, Pengmin Yang, Daoyun Zhang, and Ziying Gong were employed by the Jiaxing Yunying Medical Inspection Co., Ltd., and the Zhejiang Yunying Medical Technology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Download PDF

Editorial decision: Major revision
07 Oct, 2022
Reviews received at journal
26 Sep, 2022
Reviewers agreed at journal
07 Sep, 2022
Reviewers invited by journal
05 Sep, 2022
Editor assigned by journal
25 Aug, 2022
Editor invited by journal
16 Aug, 2022
Submission checks completed at journal
16 Aug, 2022
First submitted to journal
10 Aug, 2022

You are reading this latest preprint version

Leukocyte CH25H is a potential diagnostic and prognostic marker for lung adenocarcinoma

Status:

Version 1

Abstract

Figures

Introduction

Patients And Methods

Results

Discussion

Conclusion

Declarations

Reference

Table 1

Additional Declarations

Supplementary Files

Status:

Version 1